Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,798 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Mellitus Clear all
Active, not recruiting No phase listed Observational

Evaluating the InPen in Pediatric Type 1 Diabetes

NCT05515939
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
InPen Insulin Pen
Device
Lead sponsor
Wayne State University
Other
Eligibility
13 Years to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 1, 2026, 3:34 PM EDT
Not yet recruiting Phase 3 Interventional

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
SAB-142, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 40 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Not applicable Interventional Results available

A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens

NCT05036343
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
InPen®
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Not applicable Interventional Results available

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

NCT02558491
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Decision Support System, Usual Care
Device · Other
Lead sponsor
Daniel Chernavvsky, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 1, 2026, 3:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pancreatic Islet Transplantation Into the Gastric Submucosa

NCT01571817
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Human Pancreatic Islets
Biological
Lead sponsor
Andrew Posselt
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 1, 2026, 3:34 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

NCT06924320
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions
Interventions
MET233 and MET097, Placebo, MET097
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
381 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

NCT01742208
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 1, 2026, 3:34 PM EDT
Active, not recruiting Not applicable Interventional

Eversense® Non-adjunctive Use Post Approval Study

NCT04836546
View directory record Official record
Conditions
Diabetes
Interventions
Blood glucose meter, Eversense CGM System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
Los Angeles, California • Englewood, Colorado • Hamden, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 1, 2026, 3:34 PM EDT
Recruiting Phase 3 Interventional

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

NCT06832410
View directory record Official record
Conditions
Type 1 Diabetes, Kidney Transplant
Interventions
Biological/Vaccine
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 1, 2026, 3:34 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Milk as Treatment for Hypoglycemia

NCT00643110
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
D50 glucose
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 1, 2026, 3:34 PM EDT
Not listed Not applicable Interventional

Resistance Training in Type 1 Diabetes Mellitus

NCT05315037
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Resistance Training
Other
Lead sponsor
University of Louisville
Other
Eligibility
13 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

NCT00453375
View directory record Official record
Conditions
Diabetes, Hypoglycemia
Interventions
BHT-3021, BHT-Placebo
Drug
Lead sponsor
Bayhill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Fresno, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

NCT02430870
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TAK-648, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Anaheim, California • Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 1, 2026, 3:34 PM EDT
Completed No phase listed Observational

Analysis of B Cells From Autoimmune Individuals

NCT02747277
View directory record Official record
Conditions
Lupus Erythematosus, Rheumatoid Arthritis, Type 1 Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 1, 2026, 3:34 PM EDT
Not yet recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151
View directory record Official record
Conditions
Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
Interventions
Pembrolizumab, Porustobart
Drug
Lead sponsor
Solstice Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed Loop with Pramlintide
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

NCT00529191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

NCT00385697
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Teplizumab, Placebo
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
8 Years to 35 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 1, 2026, 3:34 PM EDT
Completed Not applicable Interventional Results available

A Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes

NCT04118374
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Standard Carb Diet, Low Carb Diet
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 1, 2026, 3:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

NCT07675590
View directory record Official record
Conditions
Health Adult Subjects, Obesity & Overweight
Interventions
TIX100, Placebo
Drug
Lead sponsor
TIXiMED, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 1, 2026, 3:34 PM EDT
Completed No phase listed Observational

Clinical Startup of the 670G Closed Loop Insulin Delivery System

NCT03017482
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Medtronic 670G
Device
Lead sponsor
Stanford University
Other
Eligibility
7 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 1, 2026, 3:34 PM EDT